文献速递新发突发、热带与寄生虫病

肯尼亚西部疟疾特异性抗体谱与青蒿素联合疗法疗效的相关性

Correlation Between Malaria-Specific Antibody Profiles and Responses to Artemisinin Combination Therapy for Treatment of Uncomplicated Malaria in Western Kenya.
PubMed 文献 · J Infect Dis · 2019-01-01

该研究基于肯尼亚西部一项随机对照试验,比较阿特美醚-苯芴醇(AL)与青蒿琥酯-甲氟喹(ASMQ)治疗非复杂性疟疾,检测血清中针对红细胞前和红细胞期抗原的总IgG。结果显示两组寄生虫斜率半衰期(t½)无显著差异,但AL组出现滞后期的人数显著多于ASMQ组(29 vs 13,P < .01)。环子孢子蛋白特异性抗体与t½正相关(AL组P = .03;ASMQ组P = .09),与清除率负相关(AL组P = .16;ASMQ组P = .02)。

要点

  • AL组出现滞后期的人数显著多于ASMQ组(29 vs 13,P < .01)。
  • 环子孢子蛋白抗体与t½正相关,与清除率负相关。
  • AL组中快速清除寄生虫者环子孢子蛋白和裂殖子表面蛋白1抗体滴度显著更高。

核心结论

  • 数据定义了与两种抗疟药不同应答相关的免疫谱,揭示既往免疫对青蒿素联合疗法疗效的影响。

研究设计与样本

  • 基于肯尼亚西部随机对照临床试验(NCT01976780)的血清样本,随机接受AL或ASMQ治疗,检测总IgG并分析免疫与寄生虫动力学指标的关系。

主要发现

  • 两组t½无显著差异,但AL组滞后期人数显著多于ASMQ组(29 vs 13,P < .01)。
  • 环子孢子蛋白特异性抗体与t½正相关(AL组P = .03;ASMQ组P = .09),与清除率负相关(AL组P = .16;ASMQ组P = .02)。
  • ASMQ组t½与年龄负相关。
  • 按t½分层,AL组快速清除者环子孢子蛋白和裂殖子表面蛋白1抗体滴度显著更高(P = .01和P = .02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of preexisting immunity on the efficacy of artemisinin combination therapy must be examined to monitor resistance, and for implementation of new treatment strategies. METHODS: Serum samples obtained from a clinical trial in Western Kenya randomized to receive artemether-lumefantrine (AL) or artesunate-mefloquine (ASMQ) were screened for total immunoglobulin G against preerythrocytic and erythrocytic antigens. The association and correlation between different variables, and impact of preexisting immunity on parasite slope half-life (t½) was determined. RESULTS: There was no significant difference in t½, but the number of individuals with lag phase was significantly higher in the AL than in the ASMQ arm (29 vs 13, respectively; P < .01). Circumsporozoite protein-specific antibodies correlate positively with t½ (AL, P = .03; ASMQ, P = .09), but negatively with clearance rate in both study arms (AL, P = .16; ASMQ, P = .02). The t½ correlated negatively with age in ASMQ group. When stratified based on t½, the antibody titers against circumsporozoite protein and merozoite surface protein 1 were significantly higher in participants who cleared parasites rapidly in the AL group (P = .01 and P = .02, respectively). CONCLUSION: Data presented here define immunoprofiles associated with distinct responses to 2 different antimalarial drugs, revealing impact of preexisting immunity on the efficacy of artemisinin combination therapy regimens in a malaria-holoendemic area. CLINICAL TRIALS REGISTRATION: NCT01976780.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Odhiambo G, Bergmann-Leitner E, Maraka M, et al. Correlation Between Malaria-Specific Antibody Profiles and Responses to Artemisinin Combination Therapy for Treatment of Uncomplicated Malaria in Western Kenya. J Infect Dis. 2019. PMID: 30649381. doi:10.1093/infdis/jiz027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。